MedTrace Logo

Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy

NCT04504747 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-06-15

No results posted yet for this study

Summary

The present project aims at identifying robust candidates for drug resistance in BC patients eligible for NAC. Its originality lies upon the combination of three different and complementary prospective approaches: from the molecular analyses of biopsies sampled before and after NAC, from in vitro BC Patient-Derived Organoids (PDO) mimicking patient's response to NAC, and from Circulating Tumor Cells (CTCs) isolated before/during/after NAC.

Conditions

  • Breast Cancer Female

Interventions

OTHER

molecular analysis of blood and tumor

RNAseq, DNAseq, CTCs

Sponsors & Collaborators

  • Institut Paoli-Calmettes

    lead OTHER

Principal Investigators

  • François BERTUCCI, Pr · Institut Paoli-Calmettes

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-03
Primary Completion
2027-12-31
Completion
2030-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04504747 on ClinicalTrials.gov